Lyell Immunopharma, Inc. (LYEL) Earnings History
Annual and quarterly earnings data from 2019 to 2025
Loading earnings history...
LYEL EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
LYEL Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | -31952.8% | -566038.9% | -762355.6% |
| 2024 | 100.0% | -588123.0% | -562285.2% |
| 2023 | 100.0% | -190006.2% | -180486.2% |
| 2022 | 100.0% | -220.9% | -216.2% |
| 2021 | 100.0% | -2016.7% | -2349.5% |
Download Data
Export LYEL earnings history in CSV or JSON format
Free sign-in required to download data
Lyell Immunopharma, Inc. (LYEL) Earnings Overview
As of May 8, 2026, Lyell Immunopharma, Inc. (LYEL) reported trailing twelve-month net income of -$246M, reflecting -1126.0% year-over-year growth. The company earned $-11.26 per diluted share over the past four quarters, with a net profit margin of -762355.6%.
Looking at the long-term picture, LYEL's historical earnings data spans multiple years. The company achieved its highest annual net income of -$129M in fiscal 2019.
Lyell Immunopharma, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including FATE (-$136M net income, -2051.1% margin), ADCT (-$137M net income, -175.3% margin), CABA (-$168M net income), LYEL has room to improve margins relative to the peer group. Compare LYEL vs FATE →
LYEL Earnings vs Peers
Earnings metrics vs comparable public companies
LYEL Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$274M | +20.0% | -$204M | $-16.06 | -762355.6% | -566038.9% |
| 2024 | -$343M | -46.2% | -$359M | $-1.31 | -562285.2% | -588123.0% |
| 2023 | -$235M | -28.1% | -$247M | $-0.93 | -180486.2% | -190006.2% |
| 2022 | -$183M | +26.8% | -$187M | $-0.74 | -216.2% | -220.9% |
| 2021 | -$250M | -22.4% | -$215M | $-1.03 | -2349.5% | -2016.7% |
| 2020 | -$204M | -58.0% | -$212M | $-0.84 | -2636.3% | -2732.6% |
| 2019 | -$129M | - | -$102M | $-0.53 | -19692.1% | -15538.7% |
See LYEL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LYEL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LYEL vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonLYEL — Frequently Asked Questions
Quick answers to the most common questions about buying LYEL stock.
Is LYEL growing earnings?
LYEL EPS fell to $-11.26, with earnings declining -1126.0%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-246M.
What are LYEL's profit margins?
Lyell Immunopharma, Inc. net margin is -762355.6%, with operating margin at -566038.9%. Below-average margins reflect competitive or cost pressures.
How consistent are LYEL's earnings?
LYEL earnings data spans 2019-2025. The declining earnings trend is -1126.0% YoY. Historical data enables comparison across business cycles.